SCHEMBL3400249

SCHEMBL3400249

O=C(Nc1ccc2nc(N[C@@H]3CCc4ccccc43)ccc2c1)Nc1ccccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.50
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
NPC1 O15118 10/20 0.49
KMT2A Q03164 4/20 0.49
RAB9A P51151 8/20 0.47
PKM P14618 2/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
HTT P42858 2/20 0.41
POLB P06746 1/20 0.41
EPHX2 P34913 1/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
NPY1R P25929 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3398554 0.90 NPC1 (0.52) NPC1KMT2ARAB9AMEN1MAPT
SCHEMBL3403165 0.88 KMT2A (0.48) NPC1KMT2ARAB9AMEN1MAPT
SCHEMBL3401343 0.88 KMT2A (0.56) TAS1R3TAS1R1NPC1KMT2ARAB9A
SCHEMBL3404267 0.86 KMT2A (0.52) NPC1KMT2ARAB9APKMSMN1; SMN2
SCHEMBL3411790 0.85 NPC1 (0.42) NPC1KMT2AMEN1MAPTNPY1R
SCHEMBL4119600 0.85 NPC1 (0.40) NPC1KMT2APOLBMEN1MAPT
SCHEMBL3404455 0.85 MCHR1 (0.45) EPHX2MAPTNFKB1NFKB2RELA
SCHEMBL3412407 0.85 JAK2 (0.47) NPC1KMT2ARAB9ASMN1; SMN2HTT
SCHEMBL3405693 0.84 NPC1 (0.45) NPC1KMT2ARAB9ASMN1; SMN2HTT
SCHEMBL3414984 0.83 AURKA (0.41) NPC1KMT2AMEN1MAPTJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US claimed
EP-2252372-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-11-24 EP claimed
WO-2009109502-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO claimed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US claimed
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
EP-2252372-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-11-24 EP disclosed
WO-2009109502-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227583-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2B NPSR1 34/4885TAS1R3 110/4885TAS1R1 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.